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OBJECTIVES The aim of this study was to determine whether nicotine, a constituent of cigarette smoke,
contributes to acute endothelial dysfunction after smoking one cigarette.
BACKGROUND Animal studies suggest that nicotine might cause an impairment of endothelium-dependent
vasodilation via an increase in oxidative stress.
METHODS Sixteen healthy smokers were entered into a randomized, observer-blinded crossover study
comparing the effects of nicotine nasal spray (1-mg nicotine) and cigarette smoke (1-mg
nicotine, 12 mg tar) on vascular reactivity in the brachial artery. Using high-resolution
ultrasound, flow-mediated dilation (FMD) and endothelium-independent, nitroglycerin-
induced dilation were assessed at baseline and 20 min after the administration of nicotine
(spray or cigarette).
RESULTS In response to similar increases in nicotine serum levels, FMD values declined from 10.2 
4.4% to 6.7  4.0% after the spray (mean difference: 3.6  2.0%, 95% confidence interval:
4.6; 2.5, p  0.0001) and from 9.4  3.8% to 4.3  2.8% after the cigarette (5.1 
2.6%,6.5;3.7, p 0.0001). Nitroglycerin-induced dilation remained similar within both
periods. Performing a period effect analysis of variance, a significant influence on FMD was
found for the mode of administration (p  0.017) and the baseline value (p  0.021). The
effect on FMD was more pronounced after the cigarette than after the spray (estimated
average effect difference: 1.9% FMD). Oxidation parameters did not increase significantly
after nicotine spray or tobacco exposure.
CONCLUSIONS These results demonstrate that nicotine alone causes acute endothelial dysfunction, although
to a lesser extent than smoking a cigarette of the same nicotine yield. However, the precise
mechanisms by which nicotine leads to this altered vascular reactivity remain unclear. (J Am
Coll Cardiol 2002;39:251–6) © 2002 by the American College of Cardiology
Cigarette smoking is an established risk factor for cardio-
vascular disease and the leading preventable cause of coro-
nary artery disease (CAD) and death in most industrialized
countries (1). However, it remains unclear whether the
increased occurrence of atherosclerosis in smokers is caused
by nicotine or by other components of tobacco smoke.
Conflicting results have been obtained with regard to the
causal role of nicotine for ischemic events. Several reports
suggest that nicotine might cause angina pectoris as well as
myocardial infarction (MI) (2). However, transdermal nic-
otine does not affect platelet activation and catecholamine
release compared with placebo, as shown by Benowitz et al.
(3). Moreover, in a randomized, double-blind, placebo-
controlled study among high-risk outpatients with cardiac
disease, transdermal nicotine did not cause a significant
increase in cardiovascular events (4). Accordingly, smokeless
tobacco use did not increase the risk of MI and did not affect
common carotid intima thickness, which is associated with
CAD (5–7).
Endothelial dysfunction, an early marker of atherosclero-
sis, has been observed in chronic smokers as well as after
acute cigarette smoking (8–10). However, the precise
mechanisms causing this altered vascular reactivity are not
fully understood and may be complex. Furthermore, the
mechanisms causing acute endothelial dysfunction may be
different from those leading to chronic endothelial dysfunc-
tion (11). Animal studies examining the effects of nicotine
on endothelial function produced controversial results.
Chronic nicotine exposure did not effect peripheral vascular
reactivity in the rat, neither at low nor at high concentra-
tions (12). In contrast, endothelium-dependent dilation of
arterioles in the hamster was modestly impaired by infusion
of low concentrations of nicotine and markedly by high
concentrations causing an increase in nicotine plasma levels
(13). Moreover, an impairment of endothelium-dependent
arteriolar dilation has been observed in the hamster after
chronic exposure to nicotine and after acute infusion of
nicotine (14,15). Reversibility of these effects by superper-
fusion with superoxide dismutase suggested a causal role of
oxidative stress (15). The concept that nicotine causes
endothelial dysfunction via an increase in oxidative stress
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has been recently supported by a study demonstrating that
exposure of endothelial cells to nicotine in vitro and in vivo
increases superoxide anion production and endothelial ad-
hesiveness for monocytes (16).
It is further conceivable that cigarette smoke contains
other substances such as carbon monoxide, inducing signif-
icant effects on vascular reactivity (17). Recently, it has been
shown that acute local exposure to nicotine impairs
endothelium-dependent vasodilation in human veins in vivo
(18).
The aim of this study was to determine whether nicotine
alone causes acute endothelial dysfunction in the brachial
artery of long-term smokers and whether nicotine replace-
ment therapy is less harmful for the integrity of endothelial
function than smoking a cigarette containing the same
amount of nicotine.
METHODS
Study design. This is an observer-blinded, randomized
crossover study examining the effects of nicotine nasal spray
and cigarette smoke on vascular reactivity in random order.
Subjects received two sprays of a nicotine nasal spray
(Nicotrol NS, Pharmacia and Upjohn, Vienna, Austria) or
smoked one cigarette (Camel Filters, R. J. Reynolds To-
bacco Co., Winston-Salem, North Carolina). Each 10-ml
spray bottle contains 100-mg nicotine (10 mg/ml) in an
inactive vehicle. After priming the delivery system for
Nicotrol NS, each actuation of the unit delivers a metered
dose spray containing approximately 0.5 mg of nicotine.
The smoking machine determined the nicotine yield for one
cigarette as 1-mg nicotine. An additional randomized,
observer-blinded crossover study compared the effects of
nicotine nasal spray and nicotine nasal spray placebo on
flow-mediated dilation (FMD) in the brachial artery.
Studies were always conducted at the same time of day
(between 3 PM and 5 PM) after fasting for 6 h. Subjects
stopped smoking 2 h before the study and did not change
smoking habits from day 1 to day 2. Blood samples were
drawn 5 min before and 10 min after the administration of
nicotine nasal spray or the ending of smoking a cigarette.
Flow-mediated dilation and nitroglycerin-induced dilation
(NMD) were evaluated at baseline and 20 min after the
administration of a nicotine nasal spray or ending of
smoking a cigarette on two subsequent days.
Study population. Sixteen young healthy smokers were
enrolled into the study. No participant had a history of
hypercholesterolemia, hypertension or diabetes mellitus.
None of the participants took antioxidative drugs before or
during this study. The investigations conformed to the
principles outlined in the Declaration of Helsinki, and the
local human subjects committee approved the study proto-
col. Written, informed consent was obtained from all
participants.
Assessment of FMD and blood flow. Endothelium-
dependent FMD after reactive hyperemia and endothelium-
independent NMD were examined in the brachial artery
according to the method described by Celermajer et al. (19).
Using high-resolution ultrasound (7.5-MHz linear array
transducer), measurements of the right brachial artery were
taken at rest after lying quietly for at least 10 min after cuff
deflation, after completing suprasystolic compression
(250 mm Hg for 4.5 min) of the right upper arm and after
sublingual application of 0.8-mg nitroglycerin. Scans of the
brachial artery were taken proximal to the bifurcation of the
radial and the ulnar artery by the same ultrasound operator.
Diameter measurements were taken from one media-
adventitia interface to the other for at least three times at
baseline and every 20 s after reactive hyperemia and after
administration of nitroglycerin. The maximum FMD and
NMD diameters were calculated as the average of the three
consecutive maximum diameter measurements after hyper-
emia and nitroglycerin, respectively. The FMD and NMD
were then calculated as the percent change in diameter
compared with baseline. The impairment of FMD after the
application of nicotine (deltaFMD) was estimated as the
percent change in FMD values compared with baseline. To
verify that suprasystolic compression of the brachial artery
caused adequate increases in blood flow, flow velocity was
measured at rest and within 15 s after cuff deflation. Blood
flow was calculated by multiplying the velocity time integral
by the heart rate and the vessel cross-sectional area (3.14 
D2/4). Reactive hyperemia was then calculated as percent
change in flow during hyperemia compared with baseline.
Determination of nicotine in serum by high-pressure
liquid chromatography (HPLC)/mass spectrometry. (S)-
()-nicotine 98% was purchased from Aldrich (Vienna,
Austria); nicotine-methyl-d3 as internal standard was ob-
tained from Cambridge Isotope Laboratories, Inc. (An-
dover, Massachusetts). Acetonitrile LiChrosolv, ammo-
nium acetate p. a. and n-butyl acetate HPLC grade was
purchased from Merck (Darmstadt, Germany), and meth-
anol Chromasolv was obtained from Riedel de Haen (Selze,
Germany).
The HPLC system consisted of Jasco Pu 980 pump, Jasco
LG-98002 Ternary Gradient Unit, CMA/260 degasser and
a Merck-Hitachi As-4000 intelligent auto sampler
equipped with 20-l sample loop and six-port valve.
Abbreviations and Acronyms
ANOVA  analysis of variance
CAD  coronary artery disease
CI  confidence interval
DIENE  conjugated dienes
FMD  flow-mediated dilation
HPLC  high-pressure liquid chromatography
LPO  lipid hydroperoxides
MDA  plasma malondialdehyde
MI  myocardial infarction
NMD  nitroglycerin-induced dilation
NO  nitric oxide
TBARS  thiobarbituric acid-reactive substances
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The mass spectrometer used was a VG Quattro (Micro-
mass, Altrinchham, United Kingdom) operating in positive
ApcI (atmospheric pressure chemical ionization) mode and
using electrospray inlet. The corona discharge needle volt-
age was set to 3.5 kV; source temperature was 100°C, and
mobile phase was acetonitrile/methanol/10 mM ammo-
nium acetate (53/32/15, v/v/v), pHa-7.8. The chromato-
graphic column used for the separation was Merck Puro-
spher Star RP-18 endcapped, 30  2 mm, and the
chromatographic separation was performed at ambient tem-
perature.
A sample preparation consisted of 500 l serum spiked
with 100 l of internal standard (400 pg/l) prepared in
methanol and extracted with 1 ml of n-butyl acetate for 10
min. The mixture was centrifuged for 5 min, and the
organic phase was transferred into the clean 1.5-ml Eppen-
dorf vial. The organic solvent was evaporated in Speedvac
concentrator at ambient temperature to near dryness. The
residue was dissolved in 100 l of mobile phase, and 20 l
of it was injected into the chromatographic system.
The increase of nicotine (delta nicotine) after the appli-
cation of nicotine was calculated as the percent change in
nicotine compared with baseline.
Determination of oxidation parameters. The measure-
ments of thiobarbituric acid reactive substances (TBARS)
are based on the reaction of malondialdehyde (MDA), a
secondary breakdown product of lipid hydroperoxides
(LPO), with thiobarbituric acid. The assay was performed
as described previously (20). Lipid hydroperoxides were
determined by a method described by Tateishi et al. (21)
using a commercial kit from Kamya company (Seattle,
Washington). Peroxidation of polyunsaturated fatty acids
leads to the formation of a conjugated diene (DIENE)
system, with a characteristic ultraviolet absorption maxi-
mum at 234 nm. The measurement of DIENE was per-
formed as described previously (22). Plasma malondialde-
hyde concentrations were measured after derivatization by
thiobarbituric acid and separation on HPLC (MDA-
HPLC), as reported previously (23,24).
Statistical analyses. Results are expressed as mean  SD.
Paired t tests (baseline vs. post-treatment values) were
performed to examine whether the administration of nico-
tine has an effect on FMD. The 95% confidence interval
(CI) for the mean difference (post  baseline values) was
calculated for both periods. Analysis of variance (ANOVA)
with the factors mode of administration (2 levels: cigarette,
coded with 1 and spray coded with 0), day of administration
(2 levels: first and second day), sequence (2 levels: spray/
cigarette and cigarette/spray), gender and the interaction
between sequence and gender, the random factor patient
within sequence and gender (16 levels) and the covariable
baseline FMD value was performed for the post-, pre-
difference to examine the different effect of the nicotine
nasal spray and the cigarette smoke on FMD. The same
ANOVA model was used to examine the different effects of
nicotine nasal spray and nicotine nasal spray placebo on
FMD. The ANOVA model was calculated using proc glm
with the test option within the SAS computer package
(Release 6.12, SAS Institute, Cary, North Carolina). Paired
t test was performed to examine whether nicotine serum
levels differed between the spray period and the cigarette
period. Correlation analysis was performed to examine the
association of changes in nicotine serum levels with the
impairment of FMD. Analysis of variance with the results
were considered significant at p 0.05.
RESULTS
Clinical and biochemical parameters. Sixteen chronic
smokers (13.4  6.5 cigarettes per day, 4.3  2.4 pack
years), eight men and eight women, were enrolled into this
study. Subjects were characterized as follows: age: mean 
SD: 24.9  1.9 years, body mass index: 21.5  2.6, total
serum cholesterol: 4.69  0.98 mmol/l, low-density li-
poprotein cholesterol: 2.55  0.80 mmol/l, high-density
lipoprotein cholesterol: 1.52  0.44 mmol/l, triglycerides:
1.35  0.76 mmol/l. Levels of nicotine were similar in both
study groups at baseline (spray vs. cigarette: 13.78  8.09
ng/ml vs. 13.25  4.57 ng/ml, p  0.805) and after
application of nicotine (spray vs. cigarette: 19.91  16.63
ng/ml vs. 18.98 6.93 ng/ml, p 0.764). Both nasal spray
and cigarette smoke resulted in significant increases of
nicotine serum levels (spray: p  0.027; cigarette: p 
0.003). With regard to TBARS, DIENE, LPO and MDA-
HPLC, no significant increases were observed either after
nicotine nasal spray or after cigarette smoking.
FMD and blood flow responses. Flow-mediated dilation
values declined from 10.2  4.4% to 6.7  4.0% after the
spray (mean post/baseline difference: 3.6  2.0%, 95%
CI:4.6;2.5, p 0.0001) and from 9.4 3.8% to 4.3
2.8% after the cigarette (mean post/baseline difference:
5.1  2.6%, 95% CI: 6.5; 3.7, p  0.0001) (Fig. 1).
The changes in FMD were influenced by the mode of
administration and the baseline value but not by the day of
administration, the sequence, the gender or the sequence 
gender interaction. On both days the mean FMD difference
was less pronounced after the spray than after the cigarette
(first day: 4.0  1.7% vs. 5.2  2.8%, second day:
3.1  2.2% vs. 5.3  2.8%). The estimated average
effect difference was 1.9% FMD. Vessel size (baseline vs.
after spray: 3.4  0.7 mm vs. 3.4  0.6 mm, p  0.096;
baseline vs. after cigarette: 3.4  0.6 mm vs. 3.4  0.5 mm,
p  0.669) and NMD (baseline vs. after spray: 15.3 
5.0% vs. 14.0 5.5%, p 0.124; baseline vs. after cigarette:
14.3  4.5% vs. 13.8  5.2%, p  0.517) remained similar
after the administration of 1-mg nicotine and were not
affected by the mode of administration. Increases in blood
flow during reactive hyperemia increased slightly but not
significantly after the spray (430  267% vs. 551  384%,
p  0.058) and after the cigarette (402  239% vs. 551 
384%, p 0.216). The impairment of FMD was not related
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to increases of nicotine serum levels after cigarette smoking
and nicotine nasal spray, respectively.
Eight of the 16 healthy smokers returned to the labora-
tory and entered into a randomized, observer-blinded cross-
over study, comparing the effects of nicotine nasal spray
(1-mg nicotine) and of nicotine nasal spray placebo on
FMD in the brachial artery. Flow-mediated dilation values
declined from 9.0  2.7% to 4.6  2.6% after the spray
(mean post/baseline difference: 4.45  2.46%, 95% CI:
6.50;2,40, p 0.0014) and from 10.2 4.1% to 9.3
2.8% after the nicotine nasal spray placebo (mean post/
baseline difference: 0.88  1.90%, 95% CI: 2.47; 0.71,
p  0.2320). Performing a period effect ANOVA, a
significant influence on FMD was found only for the mode
of administration (p 0.023) but not for the baseline value,
the day of administration, the sequence, the gender or the
interaction between gender and sequence.
DISCUSSION
Our findings show that the administration of two sprays of
nicotine nasal spray containing 1 mg of nicotine causes
endothelial dysfunction in the brachial artery of chronic
smokers, although to a lesser extent than smoking a ciga-
rette with a machine-determined nicotine yield of 1-mg
nicotine, suggesting that nicotine contributes to acute en-
dothelial dysfunction after cigarette smoking.
Cigarette smoking and cardiovascular disease. Chronic
smokers are at increased risk of acute MI, unstable angina
and sudden death (25). Moreover, cigarette smoking causes
immediate constriction of epicardial coronary arteries and
an increase in coronary artery resistance vessel tone despite
an increase in myocardial oxygen demand (26), and the
stimulation of coronary artery alpha-adrenergic receptors by
circulating or locally released catecholamines may be re-
sponsible for these effects (27). On the other hand, the
integrity of vascular endothelial cell function may play a key
role in determining the vascular response to cigarette smok-
ing (28,29). The mechanisms by which cigarette smoking
leads to endothelial dysfunction are gradually being re-
vealed. Oxidative stress may mediate this adverse effect since
cigarette smoke contains large amounts of free radicals such
as superoxide anion and hydroxyl radicals (30,31) that
degrade nitric oxide (NO) released from the endothelium.
Indeed, antioxidants such as vitamin E and C have been
shown to attenuate the impairment of endothelium-
dependent vasodilation after heavy cigarette smoking, due
to an improvement of the antioxidant status (11,30). Re-
cently, tetrahydrobiopterin supplementation has been
shown to improve FMD in long-term smokers, supporting
the concept that, in addition to the free radical burden of
cigarette smoke, a dysfunctional NO synthase due to tetra-
hydrobiopterin depletion may contribute, at least in part, to
endothelial dysfunction in smokers (32). Furthermore, in-
haling a single cigarette decreased exhaled NO in current
smokers, suggesting that it may inhibit the enzyme NO
synthase whereas inhalation of NO itself and carbon mon-
oxide, both constituents of tobacco smoke, had no effect on
exhaled NO in nonsmoking controls (33).
Nicotine and endothelial function. The concept that
nicotine causes endothelial dysfunction via an increase in
Figure 1. Flow-mediated dilation (FMD) values before and after the administration of nicotine nasal spray (1-mg nicotine) and smoking a cigarette (1-mg
nicotine, 12-mg tar), respectively.
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oxidative stress has been recently supported by animal
studies demonstrating that chronic exposure to nicotine and
acute infusion of nicotine cause an impairment of
endothelium-dependent arteriolar dilation that can be re-
stored by superperfusion with superoxide dismutase (15).
Superoxide causes a loss of the vasodilatory action of NO
and yields peroxynitrite at the same time. Subsequently,
peroxinitrite causes endothelial cell damage via membrane
lipid peroxidation (34) but also nitrates and inactivates
PGI2 synthase, leaving unmetabolized prostaglandin H2,
which causes vasospasm via the TxA2/prostaglandin H2
receptor (35). Indeed, nicotine has been shown to decrease
PGI2 synthesis in the vascular endothelium, whereas it has
no effect on thromboxane A2 production (36). However,
the contribution of PGI2 to endothelium-dependent relax-
ation may be less important than its platelet inhibitory
effects. Indeed, at least in the porcine coronary circulation,
PGI2 contributes very little to the regulation of vascular
tone (37). This study extends these findings by demonstrat-
ing that nicotine causes endothelial dysfunction in humans.
In addition to nicotine, other constituents of cigarette
smoke may contribute to acute endothelial dysfunction after
cigarette smoking, since nicotine nasal spray caused less
impairment of FMD than smoking a cigarette containing
the same amount of nicotine. However, the estimated
average intake of nicotine is 0.55 mg per nicotine nasal spray
(1-mg nicotine) and 1.43 mg per cigarette (1-mg nicotine)
(38).
Study limitations. A possible drawback of this study may
be that the nicotine plasma kinetic after the cigarette differs
from the kinetic after the spray and that this difference may
be responsible for different effects on FMD. Indeed, Gour-
lay et al. (39) showed that both venous and arterial levels of
nicotine after cigarette smoking are much higher and occur
much quicker compared with nicotine nasal spray, although
the nasal administration system has been developed to more
closely approximate cigarette delivery for improved efficacy
in clinical application and for more control in systemic
testing of nicotine (40). However, in this study, using a
protocol different from the one of Gourlay et al. (39),
increases of venous nicotine serum levels were not signifi-
cantly different between the study groups, and nicotine
serum levels before the ultrasound examination were very
similar in the spray period and in the cigarette period. Thus,
mechanisms different from pharmacokinetic factors may
have at least contributed to the more adverse effect of
cigarette smoking on FMD compared with the nicotine
nasal spray. Moreover, this study could not establish oxida-
tive stress as a relevant mechanism for nicotine-induced
endothelial dysfunction. Indeed, we cannot exclude that the
number of patients enrolled in this study may have been
insufficient to show significant increases in oxidation pa-
rameters. Thus, further studies enrolling a larger number of
patients are required to determine whether nicotine causes
endothelial dysfunction, at least in part, via an increase in
oxidative stress. However, this study was not designed to
examine the long-term effects of nicotine on endothelial
function, and the results cannot necessarily be extrapolated
to slow-release application of nicotine.
Summary and conclusions. The findings of this study
demonstrate that nicotine causes acute endothelial dysfunc-
tion in long-term smokers and suggest that there may be
other constituents of cigarette smoke that contribute to this
adverse effect. However, the precise mechanisms responsible
for this negative effect of nicotine on endothelial function
remain unclear. We conclude that nicotine replacement
therapy by nasal spray is less harmful for the endothelium
than cigarette smoking but fails to preserve the integrity of
endothelial function.
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